Suppliers and packagers for generic pharmaceutical drug: HEPARIN SODIUM; TAUROLIDINE

HEPARIN SODIUM; TAUROLIDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520	NDA	CorMedix Inc.	72990-103-10	10 VIAL, SINGLE-DOSE in 1 CARTON (72990-103-10) / 3 mL in 1 VIAL, SINGLE-DOSE (72990-103-03)	2024-04-09

Suppliers for Heparin Sodium and Taurolidine: Contract Manufacturers, Brands, and Supply Chain Sources

Last updated: May 26, 2026

Heparin sodium and taurolidine are supplied through a mix of API makers, sterile-dose manufacturers, and specialty injectables distributors. For each drug, supply is typically constrained by (1) API sourcing and purification capacity, (2) sterile fill-finish slots and validation capacity, and (3) regulatory inspection history for animal- and chemical-derived inputs (heparin) or specialty chemistry (taurolidine).

Heparin sodium suppliers and manufacturers: who makes the API and sterile drugs?

Heparin sodium is an anticoagulant used in hospitals, dialysis centers, and perioperative care. Supplier ecosystems split into: API manufacturers (typically heparin from porcine intestinal mucosa with downstream purification), and finished-dose manufacturers (heparin sodium injection in multi-dose vials/syringes).

Which companies supply heparin sodium injection for the US market?

Heparin sodium injection supply in the US typically includes:

• Brand/legacy manufacturers (historically dominant suppliers)
• Generic injectables manufacturers
• Wholesalers and GPO-distributed inventory

Because heparin shortages have repeatedly driven multi-source contracting, procurement programs often maintain a multi-vendor list that includes both FDA-approved finished-dose label holders and authorized distributors.

What are the heparin sodium API sourcing constraints that affect suppliers?

Key constraints that determine which suppliers can qualify as reliable sources:

• Feedstock availability and quality (porcine origin supply chain)
• Purification capacity for heparin sodium grade and antithrombin activity
• Compliance history for animal-derived material handling and residual testing
• Lot-to-lot potency consistency for USP-labeled strength
• Sterile manufacturing and container closure performance for injections

How many heparin sodium finished-dose suppliers typically exist?

In practice, the US market includes several suppliers at any given time, but the effective supplier base can narrow during shortage windows due to inspection outcomes, batch failures, and capacity limits at sterile fill-finish facilities.

Taurolidine suppliers and manufacturers: who provides taurolidine API and injection/solutions?

Taurolidine is used in antimicrobial and catheter-related contexts (often as part of intraluminal anti-infective solutions and related regimens). Supply chains depend on taurolidine API availability and conversion into sterile or controlled solutions, depending on the labeled product form.

Which companies supply taurolidine products?

Taurolidine supply is usually more concentrated than heparin because:

• The drug is niche relative to major anticoagulants
• Fewer FDA- or locally marketed finished-dose options exist
• Manufacturing is sensitive to controlled chemical inputs and consistent solution formulation controls

Procurement sourcing typically focuses on:

• Finished product manufacturers (solution dosage forms)
• Authorized importers/distributors for markets where product is not widely locally manufactured
• Contract manufacturers for sterile or conditioned solution fill-finish

What are the taurolidine manufacturing constraints that impact suppliers?

Common supplier-limiting factors:

• Specialty chemical synthesis and impurity control
• Batch release criteria for antimicrobial activity and solution stability
• Sterility assurance and container compatibility
• Packaging configurations that align with catheter/line use

How do supply risks compare: heparin sodium vs taurolidine suppliers?

Heparin sodium

• Higher supply breadth in normal periods, but capacity and inspection risk can compress the vendor list during shortages.
• Feedstock-derived variability and purification throughput are central to reliability.
• Hospital demand is steady and high, making procurement diversification critical.

Taurolidine

• More limited supplier base in many geographies.
• Specialty formulation and controlled input chemistry can make qualification slower.
• Risk is more about missing finished-dose supply rather than widespread capacity competition.

What supplier categories should buyers use for heparin sodium and taurolidine?

For heparin sodium

1. FDA-approved finished-dose manufacturers (injection vials/syringes)
2. Qualified API sources plus contract sterile fill-finish partners
3. Distributors with documented cold-chain not typically required but with strong lot traceability

For taurolidine

1. Finished product manufacturers for labeled solutions
2. Specialty chemical/API suppliers with demonstrated impurity control
3. Fill-finish and packaging partners for sterile or controlled solutions as required by the label

Key Takeaways

• Heparin sodium supply is driven by animal-derived API purification capacity and sterile injectables fill-finish constraints; supplier lists expand in normal periods but compress during shortage events.
• Taurolidine supply is more niche and concentrated; reliability tends to hinge on specialty API availability and solution-formulation controls.
• For procurement resilience, both drugs benefit from multi-vendor strategies across finished-dose and API-to-fill-finish pathways, with strict lot traceability requirements.

FAQs

1. How do heparin sodium shortages change the effective supplier base for hospitals?
2. Which procurement screening criteria best predict reliable heparin sodium injection supply?
3. What qualification timelines typically delay taurolidine supplier onboarding?
4. How do API lot variability risks show up in heparin sodium finished-dose potency and release?
5. What documentation should distributors provide to support lot traceability for heparin sodium and taurolidine?

References (APA)

No sources were cited.